Another study using a TMB cutoff of 20mt/Mb in 4064 NSCLC patients with the Foundation One platform containing 395 gene panels found that OS and disease control rates were significantly improved in TMB-H patients compared to TMB-L patients treated with anti-PD-1/anti-PD-L1 drugs [97]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.